logo

ERIS vs PGHL: Stock Comparison

ERIS LIFESCIENCES vs PROCTER & GAMBLE HEALTH LUpdated 22 Oct 26, 4:08 PM ISTNSE & company filings

ERIS LIFESCIENCES is the larger company by market capitalisation. PROCTER & GAMBLE HEALTH L shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

ERIS leads 2; PGHL leads 9 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

ERISPGHL

Valuation lens

What price are you paying?

Market CapContext only
₹15,432 Cr
₹8,398 Cr
P/E RatioPGHL has the lower reading
23.79x
23.53x ✓
P/B RatioERIS has the lower reading
3.95x ✓
16.01x
EPSPGHL has the higher reading
₹10.28
₹57.92 ✓
Book ValueContext only
₹281.12
₹316.01
Dividend YieldPGHL has the higher reading
0.64%
2.77% ✓

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
ERIS is the larger company
₹15,432 Cr vs ₹8,398 Cr
P/E Ratio
PGHL has a lower P/E
23.53x vs 23.79x
P/B Ratio
ERIS has a lower P/B
3.95x vs 16.01x
EPS
PGHL has higher earnings per share
₹57.92 vs ₹10.28
Dividend Yield
PGHL has a higher dividend yield
2.77% vs 0.64%
Revenue Growth (TTM YoY)
PGHL has faster revenue growth
19.1% vs 7.1%
EPS Growth (TTM YoY)
ERIS has faster EPS growth
200% vs 54.6%
ROE
PGHL has a higher ROE
62.32% vs 7.64%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricERISPGHL
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricERISPGHL
Live Price₹1,121.2₹5,062.5
Day Change-1.33%0.29%
Volume29,7178,364
52-Week High₹1,740₹6,975
52-Week Low₹1,111.1₹4,707
Distance from 52W High-35.56%-27.42%

Valuation

MetricERISPGHL
Market Cap₹15,432 Cr₹8,398 Cr
P/E Ratio23.79x23.53x
P/B Ratio3.95x16.01x
EPS₹10.28₹57.92
Book Value₹281.12₹316.01
Dividend Yield0.64%2.77%

Growth

MetricERISPGHL
Revenue Growth (TTM YoY)7.1%19.1%
EPS Growth (TTM YoY)200%54.6%
Qtr Sales Growth0%0%
Qtr Profit Growth0%0%

Profitability & Leverage

MetricERISPGHL
ROE7.64%62.32%
ROCE10.32%92.1%
Net Margin19.89%23.22%
Operating Margin29.73%31.99%
Debt to Equity0.65x0x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricERISPGHL
Promoter Holding54.14%▲ 0.22 pp0%
FII Holding5.75%▼ 0.64 pp6.42%▲ 0.09 pp
DII Holding20.72%▲ 0.37 pp12.63%▲ 0.19 pp
Public Holding19.4%▲ 0.07 pp29.13%▼ 0.29 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: ERIS LIFESCIENCES and PROCTER & GAMBLE HEALTH L.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.